drugset / Trial / NCT05118490
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Phase 4
Active not recruiting
1000 enrolled
The Aurum Institute NPC
Johns Hopkins University · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB.
Timeline
- Start
- 2023-07-19
- Primary completion
- 2025-07-11
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isoniazid | Small molecule | 300 mg | — |
| Subject | Isoniazid | Small molecule | 900 mg | — |
| Subject | Rifapentine | Small molecule | 600 mg | — |
| Subject | Rifapentine | Small molecule | 900 mg | — |